These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN; Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358 [TBL] [Abstract][Full Text] [Related]
4. Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. Rzymski P; Poniedziałek B; Fal A Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835217 [TBL] [Abstract][Full Text] [Related]
5. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands. Juncker HG; Mulleners SJ; Ruhé EJM; Coenen ERM; Bakker S; van Doesburg M; Harinck JE; Rood RD; Bouhuijs JH; Oomen M; de Groot PCJM; Pajkrt PD; Korosi A; van Goudoever PJB; van Gils MJ; van Keulen BJ EClinicalMedicine; 2022 May; 47():101393. PubMed ID: 35465077 [TBL] [Abstract][Full Text] [Related]
7. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database. Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163 [TBL] [Abstract][Full Text] [Related]
8. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD; J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD; Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053 [TBL] [Abstract][Full Text] [Related]
10. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311 [TBL] [Abstract][Full Text] [Related]
11. Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data. Primorac Padjen E; Marcec R; Zidar M; Padjen I; Katanec T; Anic B; Likic R Rheumatol Int; 2024 Feb; 44(2):273-281. PubMed ID: 38142450 [TBL] [Abstract][Full Text] [Related]
12. Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study. Bernardi FF; Mascolo A; Sarno M; Capoluongo N; Trama U; Ruggiero R; Sportiello L; Fusco GM; Bisogno M; Coscioni E; Iervolino A; Di Micco P; Capuano A; Perrella A Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896978 [TBL] [Abstract][Full Text] [Related]
13. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
14. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS. Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624 [No Abstract] [Full Text] [Related]
15. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706 [TBL] [Abstract][Full Text] [Related]
16. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Kreuzberger N; Hirsch C; Andreas M; Böhm L; Bröckelmann PJ; Di Cristanziano V; Golinski M; Hausinger RI; Mellinghoff S; Lange B; Lischetzki T; Kappler V; Mikolajewska A; Monsef I; Park YS; Piechotta V; Schmaderer C; Stegemann M; Vanshylla K; Weber F; Weibel S; Stephani C; Skoetz N Cochrane Database Syst Rev; 2022 Aug; 8(8):CD015021. PubMed ID: 35943061 [TBL] [Abstract][Full Text] [Related]